Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.
Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.
复制标题
DOI：
10.1177/24755303211067822
复制
发表时间：
2022-01-01
影响因子：
--
通讯作者：
Ritchlin, Christopher T
中科院分区：
文献类型：
--
作者：
Gondo, George C;Noe, Megan H;Ritchlin, Christopher T
简介：新型COVID-19疫苗的开发和推广为估计80%的人口接种疫苗，为结束COVID-19大流行提供了机会。目的：这项研究检查了影响银屑病成年人接受新型COVID-19疫苗可能性的观念，人口统计学和临床因素。研究方法：一项于2020年11月至2020年11月对1405名曾与患者倡导组织接触的银屑病患者进行的横断面研究。关注的主要结果是接种COVID-19疫苗的可能性。卡方检验和逻辑回归分析了个体特征与接种COVID-19疫苗可能性之间的关系。结果如下：大多数参与者（65%）在过去12个月内接种了流感疫苗，并且（64.2%）可能接种COVID-19疫苗，而35.9%的人报告不太可能接种疫苗。接种COVID-19疫苗的可能性与接种流感疫苗、种族、民族、性别、BMI、年龄、收入、PsO和PsA的严重程度有关。当控制种族，种族，男性，超重/肥胖状态，年龄，生物制品使用，疾病类型，与COVID-19结果更差相关的合并症，PsA症状和皮肤病严重程度时，接受流感疫苗的个人和家庭年收入超过75，000美元的人最有可能接受COVID-19疫苗。结论：银屑病患者的疫苗犹豫是相当大的。皮肤科医生和风湿病学家可以通过积极让患者参与这一主题来增加COVID-19疫苗的接种，使用国家银屑病基金会发布的关于COVID-19大流行期间银屑病疾病管理的指南。
Introduction: Development and dissemination of novel COVID-19 vaccines represent an opportunity to end the COVID-19 pandemic by vaccinating an estimated 80% of the population. Objectives: This study examines perceptions, and demographic and clinical factors influencing the likelihood of adults with psoriasis receiving a novel COVID-19 vaccine. Methods: A cross sectional study conducted from October-November 2020 of 1405 adults with psoriatic disease with prior contact to a patient advocacy organization. The main outcome of interest was the likelihood of receiving a COVID-19 vaccine. Chi-square tests and logistic regression examined the relationship between individual characteristics and likelihood of receiving a COVID-19 vaccine. Results: Most participants (65%) received a flu vaccination in the last 12months and were (64.2%) likely to receive a COVID-19 vaccine, while 35.9% reported being unlikely receive a vaccine. Likelihood of COVID-19 vaccination was associated with receiving the flu vaccine, race, ethnicity, sex, BMI, age, income, severity of PsO and PsA. When controlling for ethnicity, race, male sex, overweight/obese status, age, biologic use, disease type, comorbidities linked with worse COVID-19 outcomes, PsA symptoms, and skin disease severity, individuals who received the flu vaccine and those with annual household income over $75,000 were most likely to receive a COVID-19 vaccine. Conclusions: Vaccine hesitancy among individuals with psoriatic disease is considerable. Dermatologists and rheumatologists can increase COVID-19 vaccine uptake by actively engaging their patients on this topic using guidance published by the National Psoriasis Foundation on the management of psoriatic disease during the COVID-19 pandemic.